Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law
Brighter Future After 2019 Challenges?
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
You may also be interested in...
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
South Korea’s unicorn biotech Voronoi is counting on its novel lung cancer therapy to become a game changer in the market thanks to its high target selectivity and brain permeability.